Nektar Therapeutics (NKTR)

Healthcare · Biotechnology · NASDAQ

Nektar Therapeutics (NKTR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.58B and a free-cash-flow yield of -16.2%. Over the most recent reported fiscal year, revenue declined 43.9%.

Market cap	$2.58B
Trailing P/E	—
FCF yield	-16.2%
Revenue growth (YoY)	-43.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

Explore live NKTR data on Nama Insights →

Recent Congressional trades

Nektar Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Sell	$1,001 - $15,000	Sep 25, 2018
Josh Gottheimer	House	Buy	$1,001 - $15,000	Sep 25, 2018